TRIM8 and UHRF2 might affect the prognosis of osteosarcoma patients by influencing or collaborating with several important pathways, such as the p53 signaling pathway, TGF-beta signaling pathway, and cell cycle. Here, UHRF2 is linked to osteosarcoma.